AML (Acute Myeloid Leukemia)

Acute Myeloid Leukemia (AML) is a type of cancer that starts in the bone marrow. It happens when immature blood cells, called myeloid blasts, grow uncontrollably. These blasts crowd out the healthy blood cells, leading to problems like low white blood cell counts, making you more likely to get infections. AML is a serious condition that requires prompt medical attention.

Condition

What people with AML (Acute Myeloid Leukemia) report

Every report comes from a Lived member, sent anonymously.

Have you tried Cytarabine for AML (Acute Myeloid Leukemia)?

NameHow it went

About AML (Acute Myeloid Leukemia)

What It Is

Acute myeloid leukemia (AML) is a cancer of the bone marrow and blood. The bone marrow normally makes red blood cells, which carry oxygen, white blood cells, which fight infection, and platelets, which help blood clot. In AML, immature white cells called myeloblasts multiply without maturing into working cells. As these leukemia cells build up, they crowd out the healthy cells the body depends on. That crowding explains most of what people notice. Too few red cells cause tiredness, weakness, paleness and shortness of breath. Too few working white cells lead to fevers and infections. Too few platelets cause easy bruising, nosebleeds, bleeding gums or tiny red spots on the skin called petechiae. Some people also have bone or joint pain. Early symptoms can look like the flu and often appear only a few weeks before diagnosis. "Acute" means the disease usually worsens quickly, which is why it needs treatment soon after it is found. AML is the most common acute leukemia in adults and mainly affects older people: in the United States, the median age at diagnosis is about 70. It can also occur in children and younger adults. AML includes several subtypes that behave differently. One of them, acute promyelocytic leukemia (APL), can cause dangerous bleeding and clotting early on, but it responds especially well to its own specific treatment and is highly curable.

Causes & Risk Factors

AML begins when genetic changes in a blood-forming cell in the marrow cause it to keep dividing without maturing properly. For most people, the reason those changes happened is unknown. Several factors raise the risk. The most important is older age. AML is also somewhat more common in men and in people who smoke. Earlier chemotherapy or radiation therapy for another cancer can lead to AML years later, and so can heavy exposure to radiation or to benzene, an industrial chemical. People who have had another bone marrow disorder, especially myelodysplastic syndrome (a condition in which the marrow makes poorly formed blood cells), have a higher risk, as do people with certain inherited syndromes. Having a risk factor does not mean someone will develop AML, and many people diagnosed with it had none of these factors.

How It's Diagnosed

The first clue is usually a complete blood count (CBC), a routine test that measures red cells, white cells and platelets. In AML it usually shows abnormal counts. Looking at the blood under a microscope can show leukemia cells (blasts) circulating in the blood. The diagnosis is confirmed with a bone marrow aspiration and biopsy. After the skin is numbed, a hollow needle is placed into the hip bone to remove a small amount of liquid marrow and a small core of bone. AML is generally diagnosed when at least 20% of the cells in the marrow are blasts, or when certain defining genetic changes are found even with fewer blasts. The leukemia cells are then tested in detail. Flow cytometry, which reads markers on the surface of cells, confirms that the leukemia is myeloid rather than lymphoid. Chromosome and gene tests look for specific changes, such as mutations in the genes known as FLT3 and IDH (each of which has medicines aimed at it), or the swap between chromosomes 15 and 17 that defines APL. These results matter a great deal: they help predict how the leukemia is likely to behave and decide which treatments, including targeted medicines, are suitable. AML does not use the numbered stages of solid cancers. Instead, doctors describe the subtype, a genetic risk group, and whether the leukemia is new, in remission or has come back. A spinal tap (lumbar puncture) is done only when there is concern that leukemia has reached the brain or spinal fluid. Some people seek a second opinion to confirm the diagnosis and treatment plan.

Treatment Options

Treatment generally starts soon after diagnosis and comes in two phases. The first, called induction, aims to clear leukemia cells from the blood and marrow and bring about a remission: normal blood counts, fewer than 5% blasts in the marrow and no other signs of leukemia. The second, called consolidation, aims to destroy leukemia cells that remain but cannot be seen, so that the leukemia does not come back. For people healthy enough to tolerate it, intensive chemotherapy is the standard induction. It usually combines cytarabine with an anthracycline drug such as daunorubicin or idarubicin. Because it wipes out normal blood cells along with leukemia cells, it is typically given in the hospital, with transfusions and antibiotic and antifungal medicines to carry the person through several weeks of very low counts. When the leukemia has an FLT3 mutation, a targeted pill such as midostaurin (Rydapt) is added to chemotherapy. Consolidation may be more cycles of cytarabine or, for leukemia with a higher chance of returning, an allogeneic stem cell transplant. In a transplant, high-dose treatment destroys the marrow and is followed by an infusion of blood-forming cells from a donor to rebuild it. It is demanding, carries serious risks of its own and needs a suitable donor, so it is weighed against the chance that the leukemia returns. Many older adults, and people with heart, lung, kidney or other health problems, cannot safely receive intensive chemotherapy. For them, venetoclax (Venclexta), a pill that blocks a protein leukemia cells use to survive, is combined with azacitidine or decitabine (lower-intensity chemotherapy drugs) or with low-dose cytarabine. These combinations can produce remissions and are continued as long as they keep working and are tolerated. American Society of Hematology guidelines for older adults favor active treatment over supportive care alone for most people and favor venetoclax combinations over a single drug. Other targeted pills, such as ivosidenib and enasidenib for IDH mutations and gilteritinib for FLT3 mutations, are used in particular situations, including leukemia that has come back. APL is treated differently. Most people receive all-trans retinoic acid (ATRA, a vitamin A-derived medicine that forces the leukemia cells to mature) together with arsenic trioxide, often without traditional chemotherapy, and treatment begins as soon as APL is suspected. Supportive care runs through every approach: transfusions, infection prevention, nausea control and, when wanted, palliative care focused on comfort and quality of life. Some people choose supportive care alone after weighing the burden of treatment. Clinical trials are a common and reasonable option at any stage.

What to Expect

The first months after diagnosis are usually the most intense. With intensive chemotherapy, the first hospital stay often lasts several weeks while blood counts recover, followed by further cycles of treatment. Fatigue, nausea, mouth sores, hair loss and frequent transfusions are common, and infection is the main danger while white counts are low. Chemotherapy can affect fertility, so anyone who may want children in the future should raise this before treatment starts. With lower-intensity treatment, regular visits for blood tests, transfusions and treatment cycles continue for as long as it is given. Reaching remission is a major milestone, but it is not the same as a cure. Follow-up includes regular blood counts and repeat bone marrow tests. Doctors increasingly use measurable residual disease (MRD) testing, which can detect very small amounts of leukemia that a microscope would miss, to judge the risk of relapse and help decide whether a transplant or other treatment is needed. Outlook varies widely. Younger age, favorable genetic changes and a good response to the first treatment point to better results, while older age, a prior blood disorder, leukemia caused by earlier cancer treatment and adverse genetic changes make AML harder to control. Across all ages in the United States, about one in three people is alive five years after diagnosis, and death rates have been slowly falling. APL has a much better outlook than other forms once treatment is under way. For people whose leukemia cannot be cured, treatment can still extend life and ease symptoms, and planning ahead with family and the care team about goals and preferences is worthwhile.

When to Seek Help

See a doctor soon if tiredness, paleness, shortness of breath, repeated infections, easy bruising or tiny red spots on the skin persist or appear together, especially if they are getting worse over days to weeks. A simple blood count is the first step and can usually be done quickly. During treatment, a fever of 100.5 °F (38 °C) or higher, shaking chills or other signs of infection need a call to the care team right away, at any hour, because infections with low white counts can become life-threatening quickly. Check with the team before taking acetaminophen or ibuprofen for a fever, since these can hide it. Also call the care team right away for bleeding that does not stop after a few minutes of pressure, blood in vomit, urine or stool, black stools, a bad headache, vision changes or new confusion or unusual sleepiness, which can mean bleeding from low platelets. Ask your team in advance which of these signs they want you to bring to the emergency room.

Questions to Ask Your Doctor

  1. 1.What subtype and genetic risk group is my leukemia, and how do those results change my treatment options?
  2. 2.Am I a candidate for intensive chemotherapy, a lower-intensity regimen or a stem cell transplant, and what would each mean for my time in the hospital and daily life?
  3. 3.What is the goal of my treatment, and how will we know whether it is working?
  4. 4.Which symptoms should make me call you right away, and how do I reach the team after hours?
  5. 5.Is there a clinical trial that fits my situation, and should I get a second opinion at a leukemia center?

Last reviewed • Oct 2026

Educational content, not medical advice.